In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies)
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies)
Authors
Keywords
-
Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume 77, Issue 11, Pages 3163-3172
Publisher
Oxford University Press (OUP)
Online
2022-08-25
DOI
10.1093/jac/dkac298
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones
- (2021) María A. Gomis-Font et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study
- (2020) Sergio García-Fernández et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Antimicrobial Resistance in ESKAPE Pathogens
- (2020) David M. P. De Oliveira et al. CLINICAL MICROBIOLOGY REVIEWS
- Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high risk-clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2
- (2020) María PÉREZ-VÁZQUEZ et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa
- (2020) María A Gomis-Font et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update
- (2020) Ester del Barrio-Tofiño et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS
- (2020) Marta Hernández-García et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Mechanisms of Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: Results of the GERPA Multicenter Study
- (2020) Damien Fournier et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Phenotypic and Genomic Comparison of the Two Most Common ExoU-Positive Pseudomonas aeruginosa Clones, PA14 and ST235
- (2020) Sebastian Fischer et al. mSystems
- Activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered in Intensive Care Units in Spain: The SUPERIOR multicentre study
- (2019) Sergio García-Fernández et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015–17
- (2019) Sibylle H Lob et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Antibiotic resistance in Pseudomonas aeruginosa – mechanisms, epidemiology and evolution
- (2019) João Botelho et al. DRUG RESISTANCE UPDATES
- Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections
- (2019) Juan P. Horcajada et al. CLINICAL MICROBIOLOGY REVIEWS
- Activity of imipenem/relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic β-lactam resistant mutants
- (2019) Pablo Fraile-Ribot et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Global emergence of the widespread Pseudomonas aeruginosa ST235 clone
- (2018) P. Treepong et al. CLINICAL MICROBIOLOGY AND INFECTION
- Two decades of blaVIM-2-producing Pseudomonas aeruginosa dissemination: an interplay between mobile genetic elements and successful clones
- (2018) João Botelho et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
- (2018) Evelina Tacconelli et al. LANCET INFECTIOUS DISEASES
- Host and Pathogen Biomarkers for Severe Pseudomonas aeruginosa Infections
- (2017) Carlos Juan et al. JOURNAL OF INFECTIOUS DISEASES
- Deciphering the resistome of the widespreadP. aeruginosaST175 international high-risk clone through whole genome sequencing
- (2016) Gabriel Cabot et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City
- (2015) Amabel Lapuebla et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The increasing threat of Pseudomonas aeruginosa high-risk clones
- (2015) Antonio Oliver et al. DRUG RESISTANCE UPDATES
- Pseudomonas aeruginosa: new insights into pathogenesis and host defenses
- (2013) Shaan L. Gellatly et al. Pathogens and Disease
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
- (2011) A.-P. Magiorakos et al. CLINICAL MICROBIOLOGY AND INFECTION
- Wide Dispersion of ST175 Clone despite High Genetic Diversity of Carbapenem-Nonsusceptible Pseudomonas aeruginosa Clinical Strains in 16 Spanish Hospitals
- (2011) M. Garcia-Castillo et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Pseudomonas aeruginosa: all roads lead to resistance
- (2011) Elena B.M. Breidenstein et al. TRENDS IN MICROBIOLOGY
- Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study
- (2010) Marie-Laurence Lambert et al. LANCET INFECTIOUS DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started